Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Cholesterol/Lipid Disorders
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Cholesterol/Lipid Disorders
    TopAbstracts in Cholesterol/Lipid Disorders 11/27/2008 - (DGNews)
    Efficacy of statins in familial hypercholesterolaemia: a long term cohort study - (BMJ)
    TopAbstracts in Cholesterol/Lipid Disorders 11/13/2008 - (DGNews)
    Statin-Associated Myalgia Linked to Vitamin D Deficiency: Presented at AHA - (DGDispatch)
    Colesevelam Safe, Effective in Lowering Cholesterol in Children With Familial Hypercholesterolaemia: Presented at AHA - (DGDispatch)

    News archive

     Recent webcasts/CME - Cholesterol/Lipid Disorders
      Residual CV Risk and Future Treatment Strategies
      Vascular Protection and CB1 Blockade: Evolving Data
      Cardiometabolic Risk and Risk Management
      Understanding Metabolic Syndrome: Knowing the Risks
      Evidence-based Review of Lipid Treatment in 2008

      Webcasts/CME archive

       Recent cases - Cholesterol/Lipid Disorders
        Acute Myocardial Infarction in an 18 Year Old South Indian Girl with Familial Hypercholesterolemia: A Case Report
        Eruptive Xanthomas and Acute Pancreatitis in a Patient with Hypertriglyceridemia
        Abetalipoproteinemia: Two Case Reports and a Literature Review
        Familial Hypercholesterolemia with Coarctation of Aorta
        Consideration of Polypharmacology in Regards to Effective Weight Reduction: A Patient on Diabetes Medication

        Cases archive
          




        my personal edition > cholesterol/lipid disorders > news
        divider

          E-Mail this DGNews to a colleague

        DGNews


        Cipher receives FDA approval for Lipofen (CIP-Fenofibrate)

        MISSISSAUGA, CANADA -- January 13, 2006 -- Cipher Pharmaceuticals Inc. today announced that it has received final approval from the U.S. Food and Drug Administration (FDA) for CIP-Fenofibrate, the Company's novel formulation of the active ingredient fenofibrate, which is used in the treatment of hyperlipidemia.

        CIP-Fenofibrate, approved under the label as Lipofen(TM), targets a large and growing market as the three existing novel fenofibrate formulations are forecasted to exceed $1 billion in annual U.S. sales.

        "CIP-Fenofibrate is the first product from our pipeline to successfully receive FDA approval and we are actively pursuing opportunities to secure a U.S. commercial distribution agreement," said Larry Andrews, President of Cipher Pharmaceuticals. "CIP-Fenofibrate is one of three late-stage products in our pipeline. With an application for CIP-Isotretinoin under review with the FDA and preparations underway to file the CIP-Tramadol application with the FDA in the first half of 2006, we believe that the approval of CIP-Fenofibrate represents the first of a number of significant milestone events for Cipher."

        CIP-Fenofibrate received approval for three unique fenofibrate dosages: 50, 100 and 150 mg, with the 150 mg strength equivalent to Tricor(R) 160 mg under fed conditions. With CIP-Fenofibrate, the extent of absorption is increased under high-fat conditions relative to low-fat conditions.

        The approval provides for the use of CIP-Fenofibrate as adjunctive therapy to diet to reduce elevated low-density lipoprotein cholesterol (LDL-C), total-cholesterol (Total-C), triglycerides, apolipoprotein B (Apo B), and to increase high-density lipoprotein (HDL-C) in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Frederickson Type IIa, IIb) in addition to the treatment of adult patients with hypertriglyceridemia (Frederickson Types IV and V hyperlipidemia).


        SOURCE: Cipher Pharmaceuticals Inc.



        E-Mail this DGNews to a colleague   To print, use this version






        All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send